AON
28
2
CVX
14
-11
PGR
49
4
URBN
75
8
KR
46
-4
HPE
44
-4
FDX
33
-11
LH
33
-2
KMX
54
-10
NTRS
39
2
SYY
41
-2
CSCO
66
3
DG
12
-2
NRG
37
5
BRK.B
22
5
VLO
26
3
CHRW
51
-2
NUE
39
2
WFC
60
2
JCI
42
-2
AON
28
2
CVX
14
-11
PGR
49
4
URBN
75
8
KR
46
-4
HPE
44
-4
FDX
33
-11
LH
33
-2
KMX
54
-10
NTRS
39
2
SYY
41
-2
CSCO
66
3
DG
12
-2
NRG
37
5
BRK.B
22
5
VLO
26
3
CHRW
51
-2
NUE
39
2
WFC
60
2
JCI
42
-2
Financhill
Back

CytomX Therapeutics 10K Form

Sell
40

CTMX
CytomX Therapeutics

Last Price:
$1.08
Seasonality Move:
-0.08%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CTMX News And Ratings

See the #1 stock for the next 7 days that we like better than CTMX

CTMX Financial Statistics

Sales & Book Value

Annual Sales: $101.2M
Cash Flow: $-20.7M
Price / Cash Flow: 0
Annual Sales: $-0.30
Price / Book: 0

Profitability

EPS (TTM): 0.17000
Net Income (TTM): $13.8M
Gross Margin: $890K
Return on Equity: 0%
Return on Assets: 7.63%

CytomX Therapeutics Earnings Forecast

Key CytomX Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 1 years for CTMX is 100.23%.
  • The Selling, General & Administrative Expenses for CTMX have been equal to 29.66% of Gross Profit Margin.
  • The Research & Development expenses have been 76.75% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CTMX is -0.56% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

CytomX Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CTMX
CUSIP: 23284F
Website: cytomx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.04
Quick Ratio: 1.01

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CTMX Technical Analysis vs Fundamental Analysis

Sell
40
CytomX Therapeutics (CTMX) is a Sell

Is CytomX Therapeutics a Buy or a Sell?